Adenocarcinoma de la unión gastroesofágica metastásico con déficit de expresión de proteínas de reparación del ADN

Melina Pochettino; Juan Pablo Santino; Federico Cayol

doi:10.56969/oc.v26i1.13

Autores/as

Melina Pochettino Sección de Oncología Clínica, Hospital Italiano de Buenos Aires
Juan Pablo Santino Servicio de Anatomía Patológica, Hospital Italiano de Buenos Aires https://orcid.org/0000-0001-9927-4965
Federico Cayol Sección de Oncología Clínica, Hospital Italiano de Buenos Aires https://orcid.org/0000-0001-9794-2173

DOI:

https://doi.org/10.56969/oc.v26i1.13

Palabras clave:

adenocarcinoma de la unión esofagogástrica, inestabilidad microsatelital, inmunoterapia, esophagogastric junction adenocarcinoma, microsatellite instability, immunotherapy

Resumen

Se presenta a continuación el caso clínico de una mujer de 69 años con diagnóstico de adenocarcinoma de la unión gastroesofágica localmente avanzado, que realizó tratamiento con esquema CROSS y posterior esofagectomía. Presentó recaída en un sitio poco frecuente, a nivel de la base de la lengua. Se realizó la caracterización molecular de la lesión que demostró pérdida de expresión de proteínas de reparación del ADN por mismatch.

Citas

Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro- oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687–97. DOI: https://doi.org/10.1016/S0140-6736(10)61121-X

Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021; 398: 27-40. DOI: https://doi.org/10.1016/S0140-6736(21)00797-2

Kato K, Shah MA, Enzinger P, et al. KEYNOTE-590: Phase III study of first-line chemotherapy with or without

pembrolizumab for advanced esophageal cancer. Future Oncol 2019; 15: 1057-66. DOI: https://doi.org/10.2217/fon-2018-0609

Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 2018; 5: e180013. DOI: https://doi.org/10.1001/jamaoncol.2018.0013

Kojima T, Shah MA, Muro K, et al. Randomized Phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol 2020; 38: 4138-48. DOI: https://doi.org/10.1200/JCO.20.01888

Kato K, Doki Y, Ura T, et al. Nivolumab in advanced esophageal squamous cell carcinoma (ATTRACTION-1/ONO- 4538-07): Minimum of five-year follow-up. J Clin Oncol 2021; 39: 207. DOI: https://doi.org/10.1200/JCO.2021.39.3_suppl.207

Azad NS, Gray RJ, Overman MJ, et al. Nivolumab Is effective in mismatch repair-deficient noncolorectal cancers: results from Arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study. J Clin Oncol 2020; 38: 214-22. DOI: https://doi.org/10.1200/JCO.19.00818

Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study. J Clin Oncol

; 38: 1-10.